InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.600
-0.020 (-1.23%)
Jun 16, 2026, 4:00 PM EDT - Market closed
InflaRx Market Cap
InflaRx has a market cap or net worth of $235.67 million as of June 16, 2026. Its market cap has increased by 329.46% in one year.
Market Cap
235.67M
Enterprise Value
190.73M
1-Year Change
329.46%
Ranking
Category
Stock Price
$1.60
Market Cap Chart
Since November 8, 2017, InflaRx's market cap has decreased from $351.36M to $235.67M, a decrease of -32.93%. That is a compound annual growth rate of -4.53%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 16, 2026 | 235.67M | 244.42% |
| Dec 31, 2025 | 68.42M | -52.95% |
| Dec 31, 2024 | 145.44M | 51.53% |
| Dec 29, 2023 | 95.98M | -29.96% |
| Dec 30, 2022 | 137.03M | -34.85% |
| Dec 31, 2021 | 210.33M | 48.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 8, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| VERAXA Biotech AG | 238.56M |
| Sol-Gel Technologies | 238.21M |
| Foghorn Therapeutics | 235.44M |
| AC Immune | 235.11M |
| Entrada Therapeutics | 234.22M |
| Anavex Life Sciences | 233.53M |
| Adagene | 233.24M |
| Fulcrum Therapeutics | 230.55M |